SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.
（深圳市海普瑞藥業集團股份有限公司）

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 9989)

INTERIM RESULTS ANNOUNCEMENT
FOR THE SIX MONTHS ENDED JUNE 30, 2024

Board)
Company Hepalink)
Group, we, our us)
Reporting Period)

FINANCIAL HIGHLIGHTS

	For the six months ended June 30,		
	2024	2	%
	RMB'000	RMB'000	
	2,828,657	2	4
	999,274	5	4
	35.3%	5	
	663,684	3	8
	2,202,718	1	4
	34.3%	3	
	1,294,842	(	

FINANCIAL HIGHLIGHTS

INTERIM CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS
For the six months ended June 30, 2024

		Six months ended June 30,	
		2024	0
	Notes	RMB'000	RMB'000
		(unaudited)	(
REVENUE	4	2,828,657	2
,		(1,829,383)	(
Gross profit		999,274	5
	5	406,625	0
		(191,911)	(
		(279,610)	(
		11,446	(
		(15,906)	(
	6	(84,504)	(
		(77,765)	(

INTERIM CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

For the six months ended June 30, 2024

	Six months ended June 30,	
	2024	0
	RMB'000	RMB'000
	(unaudited)	(
PROFIT FOR THE PERIOD	662,836	2
OTHER COMPREHENSIVE INCOME		

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

June 30, 2024

	Notes	June 30, 2024 RMB'000 (unaudited)	[illegible] 0 RMB'000 (
NON-CURRENT ASSETS			
[illegible]		2,648,093	2
[illegible]		203,977	0
[illegible]		2,336,835	2
[illegible]		366,955	9
[illegible]		508,835	1
[illegible]		606,221	0
[illegible]		817,111	1
[illegible]		259,425	0
[illegible]		117,400	0
[illegible]		107,022	[illegible]
Total non-current assets		7,971,874	8
CURRENT ASSETS			
[illegible]		6,022,241	6
[illegible]	11	1,314,094	1
[illegible]		11,015	0
[illegible]		648,765	6
[illegible]		45,653	5
[illegible]		332,872	4
[illegible]		548	[illegible]
[illegible]		2,280	0
[illegible]		21,450	8
[illegible]		2,202,718	1
Total current assets		10,601,636	0
Total assets		18,573,510	9

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (Continued)

June 30, 2024

	Notes	June 30, 2024 RMB'000 (unaudited)	[illegible] RMB'000 (
CURRENT LIABILITIES			
[illegible]	12	378,167	[illegible]
[illegible]			[illegible]
[illegible]		431,825	[illegible]
[illegible]		367,641	[illegible]
[illegible]		2,992,776	[illegible]
[illegible]		186,129	[illegible]
[illegible]		89,937	[illegible]
[illegible]		33,434	[illegible]
Total current liabilities		4,479,909	[illegible]
NON-CURRENT LIABILITIES			
[illegible]		1,496,572	[illegible]
[illegible]		28,254	[illegible]
[illegible]		242,464	[illegible]
[illegible]		32,996	[illegible]
[illegible]		10,242	[illegible]
[illegible]		73,650	[illegible]
Total non-current liabilities		1,884,178	[illegible]
NET CURRENT ASSETS		6,121,727	[illegible]
TOTAL ASSETS LESS CURRENT LIABILITIES		14,093,601	[illegible]
Net assets		12,209,423	[illegible]
SHAREHOLDER EQUITY			
[illegible]		1,467,296	[illegible]
[illegible]		10,667,729	[illegible]
[illegible]		12,135,025	[illegible]
[illegible]		74,398	[illegible]
Total shareholder equity		12,209,423	[illegible]

MANAGEMENT DISCUSSION AND ANALYSIS

Overview

CDMO)

API)

EMA)

R&D)

Cytovance)

(SPL)

PRC)

HighTide）

Sales

Heparin Industrial Chain Business

CDMO Business

Innovative Drugs and Innovative Business

CTTQ)

Oregovomab

AR-301 (Salvecin)

Aridis)

EMA)

RVX-208 (Apabetalone)

H1710

Outlook

Financial Review

Revenue

	For the six months ended June 30,				
	2024 sales amount RMB 000 (unaudited)	2024 % of revenue		%	Year-on-year increase/ decrease (%)
	2,245,298	79.4%			
	1,453,516	51.4%			
	747,599	26.4%			
	44,183	1.6%			
	560,378	19.8%			
	22,981	0.8%			
Total	2,828,657	100%			

Notes:

Finance Costs

Taxation

Profit Attributable to Equity Holders of the Company

Earnings per Share

Liquidity and Financial Resources

Treasury Policies

[illegible]

Foreign Currency Risk

[illegible]

Liquidity and Financial Resources

[illegible]

Capital Structure

[illegible]

Pledge of Assets

[illegible]

Contingent Liabilities

[illegible]

Asset-liability Ratio

[illegible]

Interest Rate Risk

[illegible]

Indebtedness

	As at June 30, 2024 RMB'000 (unaudited)	[illegible] RMB'000 (
[illegible]	4,489,348	5
[illegible]	107,084	8
[illegible]	4,596,432	5
[illegible]	(2,280)	(
[illegible]	4,594,152	5

	As at June 30, 2024 RMB'000 (unaudited)	[illegible] RMB'000 (
[illegible]	2,992,776	3
[illegible]	823,328	7
[illegible]	124,652	4
[illegible]	548,592	9
[illegible]	4,489,348	5

[illegible]

[illegible]

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

For the six months ended June 30, 2024

1. Corporate Information

PRC)

Hong Kong Stock Exchange

Group)

2.1 Basis of Preparation

IAS)

IFRSs)

RMB)

2.2 Changes in Accounting Policies and Disclosures

[illegible]

[illegible]

[illegible] Lease Liability in a Sale and Leaseback

[illegible] Classification of Liabilities as Current or Non-current (the “2020 Amendments”)

[illegible] Non-current Liabilities with Covenants (the “2022 Amendments”)

[illegible] Supplier Finance Arrangements

[illegible]

([illegible]

3. Operating Segment Information

	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
	1	6	5	6	2
	1	1	4	1	2
	2	1	5	5	5
					(
					2
	0	3	7	2	1
					(
					0
					(
					(
					(
					(
					(
					6

Geographical information

(a) Revenue from external customers

	For the six months ended June 30,	
	2024	[illegible]
	RMB'000	RMB'000
	(unaudited)	(
[illegible]	6,678	4
[illegible]	580,353	5
[illegible]	1,390,708	1
[illegible]	187,627	[illegible]
[illegible]	663,291	[illegible]
	2,828,657	2

(b) Non-current assets

	As at	
	June 30,	[illegible]
	2024	[illegible]
	RMB'000	RMB'000
	(unaudited)	(
[illegible]	2,825,277	2
[illegible]	3,305,483	3
[illegible]	157,000	[illegible]
[illegible]	1,357	[illegible]
[illegible]	6,289,117	6

Information about major customers

[illegible]

[illegible]

[illegible]

[illegible]

4. Revenue

Revenue from contracts with customers

For the six months ended June 30, 2024 (unaudited)

Segment	Finished dose pharmaceutical products RMB'000	API RMB'000	CDMO RMB'000	Others RMB'000	Total RMB'000
Type of goods or services					
	1,453,516	747,599		44,183	2,245,298
			560,378		560,378
				22,981	22,981
	1,453,516	747,599	560,378	67,164</Lang (en-GB)/MCID 1388 >>BDC BT,	

	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
Type of goods or services					
	1,547,336	698,062		44,128	2,289,526
			395,381		395,381
				21,339	21,339
	1,547,336	698,062	395,381	65,467	2,706,246
Timing of revenue recognition					
	1,547,336	698,062		44,128	2,289,526
			133,593	6,682	140,275
			261,788	14,657	276,445
	1,547,336	698,062	395,381	65,467	2,706,246

	For the six months ended June 30,	
	2024	[illegible]
	RMB'000	RMB'000
	(unaudited)	(
	22,859	[illegible]
	425,851	[illegible]
	448,710	[illegible]

([illegible]

Sale of products

[illegible]

CDMO services

[illegible] FFS)

[illegible]

	As at	
	June 30,	[illegible]
	2024	[illegible]
	RMB'000	RMB'000
	(unaudited)	(
[illegible]	355,242	[illegible]

[illegible]

5. Other Income and Gains

	For the six months ended June 30,	
	2024	[illegible]
	RMB'000	RMB'000
	(unaudited)	(
Other income		
[illegible]	18,596	[illegible]
[illegible]		
[illegible]	1,281	[illegible]
[illegible]	3,003	[illegible]
[illegible]	207,876	[illegible]
	230,756	[illegible]
Other gains		
[illegible]	(12,134)	[illegible]
[illegible]	1,361	[illegible]
[illegible]		
[illegible]	(96,283)	[illegible]
[illegible]	8,607	(
(		
[illegible]	(583)	[illegible]
[illegible]	272,018	[illegible]
[illegible]	2,883	[illegible]
	175,869	[illegible]
	406,625	[illegible]

* [illegible]

[illegible]

1

* [illegible]

[illegible]

6. Finance Costs

	For the six months ended June 30,	
	2024	0
	RMB'000	RMB'000
	(unaudited)	(
	71,970	9
	6,796	1
	776	2
	4,962	0
	84,504	6

7. Profit before Tax

	For the six months ended June 30,	
	2024	0
	RMB'000	RMB'000
	(unaudited)	(
,	1,443,136	1
,	386,247	9
	128,038	6
	18,686	9
	27,651	7
	81,041	9
	2,698	4
	229,924	3
	52,627	9
	(18,596)	(
	84,504	6
	12,134	(
	(1,361)	(
	(8,607)	2
	96,283	(
,	583	(
	(272,018)	(
	(11,446)	4
	(13,934)	(

*

*

8. Income Tax Expense

	For the six months ended June 30,	
	2024	0
	RMB'000	RMB'000
	(unaudited)	(
	4,776	3
	58,720	(
	4,525	4
	(5,041)	8
	62,980	4
	50,552	9
	(2,020)	3
	(6,699)	(
	41,833	3
	104,813	5

9. Dividends

	For the six months ended June 30,	
	2024	0
	RMB'000	RMB'000
	(unaudited)	(
		6

10. Earnings per Share Attributable to Ordinary Equity Holders of the Parent

	For the six months ended June 30,	
	2024	[illegible]
	RMB'000	RMB'000
	(unaudited)	(
[illegible]	663,684	[illegible]

	For the six months ended June 30,	
	2024	[illegible]
	(unaudited)	(
[illegible]	1,467,296,204	[illegible]

11. Account Receivables

	As at June 30, 2024	As at [illegible]
	RMB'000	RMB'000
	(unaudited)	(
[illegible]	1,342,426	[illegible]
[illegible]	2,429	[illegible]
[illegible]	(30,761)	(
	1,314,094	[illegible]

	As at June 30, 2024 RMB'000 (unaudited)	[illegible] 0 RMB'000 (
[illegible]	1,009,476	1
[illegible]	304,769	9
[illegible]	7,400	0
[illegible]	23,210	2
	1,344,855	1
[illegible]	30,761	0
	1,314,094	1

	As at June 30, 2024 RMB'000 (unaudited)	[illegible] 0 RMB'000 (
[illegible]	40,039	4
[illegible]	(8,491)	2
[illegible]		(
[illegible]	(787)	1
	30,761	0

12. Account Payables

	As at June 30, 2024 RMB'000 (unaudited)	[illegible] 0 RMB'000 (
[illegible]	378,167	[illegible]

[illegible]

	As at June 30, 2024 RMB'000 (unaudited)	[illegible] 0 RMB'000 (
[illegible]	373,914	[illegible]
[illegible]	3,276	[illegible]
[illegible]	476	[illegible]
[illegible]	501	[illegible]
	378,167	[illegible]

[illegible]

13. Share Capital

	As at June 30, 2024 RMB'000 (unaudited)	[illegible] 0 RMB'000 (
[illegible]	1,467,296	[illegible]

Use of Proceeds from the H Share Listing of the Company

H Share Listing)

Net Proceeds)

Prospectus)

Announcement)

Business objectives	Revised allocation of unutilized Net Proceeds as at the date of the Announcement (RMB million)	Unutilized Net Proceeds as at December 31, 2023 (RMB million)	Utilized Net Proceeds during the six months ended June 30, 2024 (RMB million)	Cumulative utilization of Net Proceeds as of June 30, 2024 (RMB million)	Unutilized Net Proceeds as at June 30, 2024 (RMB million)
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]

Significant Investments

Purchase, Sale or Redemption of Listed Securities

Material Acquisitions and Disposals of Subsidiaries, Associates and Joint Ventures

Events after the Reporting Period

Employee and Remuneration Policy

Compliance with the Model Code for Securities Transactions by Directors of Listed Issuers

Model Code)

Review of Interim Results by the Audit Committee

Audit Committee)

Interim Dividends

Publication of 2024 Interim Results Announcement and Interim Report

Appreciation

Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Li Li
Chairman

As at the date of this announcement, the executive directors of the Company are Mr. Li Li, Ms. Li Tan, Mr. Shan Yu and Mr. Zhang Ping; and the independent non-executive directors of the Company are Dr. Lu Chuan, Mr. Huang Peng and Mr. Yi Ming.

This announcement contains forward-looking statements relating to the business outlook, estimates of financial performance, forecast business plans and growth strategies of the Group. These forward-looking statements are based on information currently available to the Group and are stated herein on the basis of the outlook at the time of this announcement. They are based on certain expectations, assumptions and premises, some of which are subjective or beyond control of the Group. These forward– looking statements may prove to be incorrect and may not be realised in the future. Underlying these forward-looking statements are a large number of risks and uncertainties. In light of the risks and uncertainties, the inclusion of forward-looking statements in this announcement should not be regarded as representations by the Board or the Company